Natera announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation to its multi-cancer early detection (MCED) assay. The blood-based test analyzes cell-free DNA to screen for multiple cancers, according to the company’s press release.
The announcement addresses a central challenge in cancer screening: reaching cancers for which routine screening options are limited. The National Cancer Institute (NCI) notes that multi-cancer detection tests could expand screening to additional organ sites through a single blood sample. Whether this approach translates into fewer cancer deaths remains a question requiring rigorous clinical evaluation.
FDA Assessed Data From 12 Cancer Types
According to Natera, the FDA reviewed data from 12 cancer types, considering sensitivity, specificity, and cancer signal origin performance. The release does not identify those cancers or disclose numerical performance results, study size, or stage-specific detection rates.
These measures address different aspects of screening performance. Sensitivity describes how often a test identifies cancer when it is present, while specificity describes how often it returns a negative result in people without cancer. Cancer signal origin assessment concerns identifying the likely source of a detected signal, potentially helping direct subsequent diagnostic evaluation.
Alexey Aleshin, MD, Natera’s corporate chief medical officer and general manager of oncology and early cancer detection, said:
“Too many cancers are diagnosed after they’ve progressed, simply because limited screening options exist.”
What FDA Breakthrough Device Designation Means
The designation provides access to a program intended to accelerate device development, assessment and regulatory review. Manufacturers can engage with FDA experts on development questions and receive prioritized review of regulatory submissions.
Breakthrough Device designation is distinct from FDA marketing authorization. Devices must still meet the agency’s applicable safety and effectiveness standards before receiving approval, clearance, or De Novo authorization. The designation therefore represents a development milestone, rather than permission to market the assay.
From Detecting a Signal to Improving Outcomes
The broader significance of multi-cancer screening depends on what happens after a blood test flags a possible cancer. A positive result requires diagnostic confirmation, which may involve imaging or biopsy. Screening performance must therefore be evaluated alongside the consequences of follow-up testing, including false-positive results and unnecessary procedures.
NCI also emphasizes that multi-cancer detection testing does not replace recommended screening for individual cancers. Establishing clinical benefit requires evidence that screening improves meaningful patient outcomes while balancing potential harms.
For Natera, the immediate next step described in the announcement is continued collaboration with the FDA as the company advances its early-detection program. The release does not provide a launch date or a timeline for a marketing submission.
Read also on OncoDaily: Telisotuzumab Adizutecan (Temab-A) Earns FDA Breakthrough Therapy Designation in c-Met–Expressing NSCLC
